Abstract
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | EPO2200 |
| Tidsskrift | European Journal of Neurology |
| Vol/bind | 26 |
| Udgave nummer | Suppl 1 |
| Sider (fra-til) | 665-665 |
| Antal sider | 1 |
| ISSN | 1351-5101 |
| Status | Udgivet - 2019 |
| Udgivet eksternt | Ja |
Citer dette
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
I: European Journal of Neurology, Bind 26, Nr. Suppl 1, EPO2200, 2019, s. 665-665.
Publikation: Bidrag til tidsskrift › Konferenceartikel › Forskning › peer review
TY - GEN
T1 - Molecular mimicry and host response to pathogens in multiple sclerosis vs. tuberculosis
T2 - An in silico neuroimmunology approach
AU - Vavougios, G.
AU - Breza, M.
AU - Mavridis, T.
AU - Krogfelt, K.
AU - Pelidou, S.
AU - Doskas, T.
PY - 2019
Y1 - 2019
N2 - ePosterBackground and aims: Type 2 Diabetes Mellitus (DM) as a risk factor for Alzheimer’s disease (AD) has been studied in recent years; however, no clear evidence of association has been found yet. As potential biomarker for AD, plasma beta amyloid level is likewise under study by researchers. We examined the correlation between plasma beta amyloid levels and cognitive functions of Type 2 DM patients with Dementia as indicated by their neurocognitive assessment scores with the end in view of finding a less invasive early detection of AD among diabetic patients. Methods: In this cross sectional study, 100 Type 2 DM patients with dementia underwent plain cranial CT scan, plasma beta amyloid, MMSE and MoCA tests. Patients were categorised as having vascular or non vascular dementia using NINDS-AIREN criteria. Elevated plasma beta amyloid (≥1.1pg/ml) was used as biomarker for AD. Results: Among Type 2 DM patients with dementia, there was an increased prevalence of AD (46.7%). The prevalence of vascular dementia was 6%. Among patients with Non Vascular Dementia, majority (51.3%) had elevated beta amyloid. There was no significant correlation between both MMSE (r=-0.0192, p=0.8557) and MoCA scores (r=0.0939, p=0.3731) with beta amyloid level.
AB - ePosterBackground and aims: Type 2 Diabetes Mellitus (DM) as a risk factor for Alzheimer’s disease (AD) has been studied in recent years; however, no clear evidence of association has been found yet. As potential biomarker for AD, plasma beta amyloid level is likewise under study by researchers. We examined the correlation between plasma beta amyloid levels and cognitive functions of Type 2 DM patients with Dementia as indicated by their neurocognitive assessment scores with the end in view of finding a less invasive early detection of AD among diabetic patients. Methods: In this cross sectional study, 100 Type 2 DM patients with dementia underwent plain cranial CT scan, plasma beta amyloid, MMSE and MoCA tests. Patients were categorised as having vascular or non vascular dementia using NINDS-AIREN criteria. Elevated plasma beta amyloid (≥1.1pg/ml) was used as biomarker for AD. Results: Among Type 2 DM patients with dementia, there was an increased prevalence of AD (46.7%). The prevalence of vascular dementia was 6%. Among patients with Non Vascular Dementia, majority (51.3%) had elevated beta amyloid. There was no significant correlation between both MMSE (r=-0.0192, p=0.8557) and MoCA scores (r=0.0939, p=0.3731) with beta amyloid level.
M3 - Conference article
SN - 1351-5101
VL - 26
SP - 665
EP - 665
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - Suppl 1
M1 - EPO2200
ER -